Vivoryon Therapeutics AG (VVY) Financial Statements

1 Followers

Vivoryon Therapeutics AG Financial Overview

Vivoryon Therapeutics AG's market cap is currently €32.58M. The company's EPS TTM is €-0.33; its P/E ratio is -3.52; Vivoryon Therapeutics AG is scheduled to report earnings on June 11, 2026, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	€ 0.00	€ 0.00	€ -3.62M	€ 0.00	€ 10.76M
Gross Profit	€ -147.00K	€ -147.00K	€ -3.10M	€ -161.00K	€ 9.03M
Operating Income	€ -9.18M	€ -20.96M	€ -28.84M	€ -29.13M	€ -12.81M
EBITDA	€ -9.03M	€ -20.34M	€ -28.35M	€ -28.17M	€ -12.03M
Net Income	€ -8.85M	€ -20.57M	€ -28.34M	€ -28.16M	€ -12.65M
Balance Sheet
Cash & Short-Term Investments	€ 5.62M	€ 9.37M	€ 28.58M	€ 26.55M	€ 14.66M
Total Assets	€ 7.52M	€ 11.28M	€ 30.83M	€ 31.38M	€ 24.52M
Total Debt	€ 108.00K	€ 102.00K	€ 38.00K	€ 132.00K	€ 224.00K
Net Debt	€ -5.51M	€ -9.26M	€ -18.52M	€ -26.42M	€ -14.44M
Total Liabilities	€ 2.79M	€ 3.40M	€ 4.55M	€ 4.87M	€ 7.96M
Stockholders' Equity	€ 4.73M	€ 7.88M	€ 26.28M	€ 26.51M	€ 16.56M
Cash Flow
Free Cash Flow	€ -8.46M	€ -19.18M	€ -22.05M	€ -21.81M	€ -11.29M
Operating Cash Flow	€ -8.46M	€ -19.17M	€ -21.54M	€ -21.79M	€ -11.26M
Investing Cash Flow	€ -6.00K	€ 10.00M	€ -10.51M	€ -13.00K	€ -28.00K
Financing Cash Flow	€ 4.71M	€ -57.00K	€ 24.16M	€ 33.38M	€ -827.00K

Currency in EUR

Vivoryon Therapeutics AG Earnings and Revenue History

Income Statement >

Vivoryon Therapeutics AG Debt to Assets

Balance Sheet >

Vivoryon Therapeutics AG Cash Flow

Cash Flow >

Vivoryon Therapeutics AG Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >